Opinion|Videos|February 27, 2025
Beyond HER2: Expanding the Biomarker Testing Landscape in Metastatic Breast Cancer
Panelists discuss how HER2 testing optimization requires multisite sampling and quantitative assessment methods to account for intratumoral heterogeneity. Beyond HER2, biomarkers such as PI3K mutations, hormone receptor status, and tumor mutational burden can guide therapy selection for metastatic breast cancer (mBC), enabling more personalized treatment approaches.
Advertisement
Episodes in this series
Video content above has been prompted by the following:
- How can we optimize HER2 testing and antibody-drug conjugate treatment selection considering tumor heterogeneity across different cancer sites?
- Are there additional biomarkers beyond HER2 that can help guide mBC therapy selection?
Advertisement
Related to this article
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
New warnings cover every GLP-1 RA, including semaglutide, tirzepatide, and orforglipron.
At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
2
Understanding Kratom: Pharmacology, Safety, and Regulation
3
Survodutide Shows Cardiovascular Safety in SYNCHRONIZE-CVOT
4
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
5